YOU ARE HERE:
Triomune approved for PEPFAR use
The US Food and Drug Administration announced last week that it has granted tentative approbal to a fixed dose triple combination of the antiretroviral drugs nevirapine, stavudine and lamivudine. The product is marketed by Cipla as Triomune, and will now be available for purchase by United States PEPFAR-funded treatment programmes worldwide (PEPFAR is the President's Emergency Plan for AIDS Relief, founded in 2003 to deliver antiretroviral treatment and HIV prevention in developing countries).
Triomune is already one of the most widely used generic antiretroviral products in developing countries because it combines three drugs recommended for first-line therapy by the World Health Organization into one tablet.
According to the Boston Globe, generic antiretroviral drugs now account for almost 70% of PEPFAR-funded HIV treatment in Haiti, Nigeria and Zambia, three of the 15 countries targeted by the programme.
Triomune is already one of the most widely used generic antiretroviral products in developing countries because it combines three drugs recommended for first-line therapy by the World Health Organization into one tablet.
According to the Boston Globe, generic antiretroviral drugs now account for almost 70% of PEPFAR-funded HIV treatment in Haiti, Nigeria and Zambia, three of the 15 countries targeted by the programme.
aidsmap resources
Africa news
- The Lancet: HIV is a global disaster
- Most HIV infections in Zambia and Rwanda happen in marriage: prevention programmes for couples recommended
- Opt-out testing increases HIV counselling and testing rates in South African TB clinics
New drugs news
- Atazanavir approved for first-line treatment in Europe
- Nearly all patients with NNRTI resistance could benefit from etravirine, UK analysis shows
- New way of attacking HIV looks promising in early trial